A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or…
Articles by Marisa Wexler, MS
A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to…
The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple…
The European Commission (EC) has approved Sanofi‘s Sarclisa (isatuximab), in a triple combination with Pomalyst (pomalidomide)…
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might…
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and…
Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with…
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate…
For people with multiple myeloma who don’t respond well to an initial type of therapy, quickly switching to another…
People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to…